TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07833943: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, and Multiple Dose Study to Evaluate the Safety, Efficacy, Pharmacokinetic, and Immunogenicity of STSP-0902 in Patients With Oligozoospermia and/or Asthenozoospermi

Sponsor: Staidson (Beijing) Biopharmaceuticals Co., Ltd · Phase: PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 72 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$11,040,000

Rescue Site Savings

+$7,279,500

Unlock Full NCT07833943 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07833943 Rescue Dossier →